Bringing the ALS Patient Perspective to Canada’s Drug Policy Reform Debate

ALS Action Canada Member Dr. Andrew Darke, who is living with ALS, is contributing to the national debate on drug policy reform. In a Financial Post commentary with Nigel Rawson and John Adams, he examines how recent U.S. trade policies strengthen the case for reforms to Canada’s drug approval, pricing and coverage processes. For ALS Action Canada, advocating for timely and equitable access to innovative treatments remains a key priority.

ALS in Focus: The Challenges Are Well Documented. What Happens Next?

ALS Action Canada is calling for meaningful action following the release of Canada’s Drug Agency’s final assessment of ALS care and support — a report shaped in part by the contributions of three of our Members and documenting challenges long familiar to people living with ALS and their caregivers.

Jodee Karlowsky’s Story: Finding Strength in a Collective Voice

ALS Caregiver, ALS Action Canada Member and Membership Committee Member When someone is diagnosed with ALS, the impact extends far beyond the person living with the disease. Families find themselves navigating an entirely new reality, often watching the lives they had planned change in ways they could never have anticipated. For Jodee Karlowsky, whose husband […]

A Missed Opportunity: ALS Research Funding Absent from the 2026 Federal Budget

ALS Action Canada is deeply disappointed that the 2026 federal budget failed to include a proposed $50 million investment in ALS research over five years. Following our advocacy efforts on Parliament Hill alongside coalition partners, we continue calling for meaningful federal action to accelerate progress toward effective treatments and a cure.

Inspired to Act: Caryn Lieberman on Courage and Advocacy

Some stories stay with you long after the interview ends. For Global News Toronto journalist Caryn Lieberman, Louis Del Re’s story is one of them. Caryn first learned about Louis, an ALS Action Canada Board Director, through his uncle, a Toronto police officer she was working with on a story. Moved by what she heard […]

A Patient Perspective on ALS Clinical Trials and Timely Access

How much evidence should be required before people living with ALS can access a promising new therapy?

In a newly published Reader Response in Neurology, Dr. Andrew Darke, an ALS Action Canada Advocacy Committee Member, responds to a recent article examining what its authors describe as a “credibility gap” in ALS clinical trials, due to what it describes as a “Clinical Trial Industrial Complex” involving ALS neurologists and manufacturers of new drugs for ALS.

Challenging Barriers to ALS Treatment Access: Bringing Our Patient Voice to Canada’s Drug Agency

From time to time, we hear of pALS who are not eligible to get Radicava under their provincial or private insurance plan. Recently we heard of a pALS who had been on Radicava, but were later told they were no longer eligible to receive it. The reason for this is the criteria for who is eligible for drugs, and who can continue to receive them under the provincial drug benefit plans. These criteria are developed by Canada’s Drug Agency (CDA), which is a separate agency from Health Canada which approves drugs as safe and effective
to be marketed.

My ALS Journey: Terry’s Story

After years of searching for answers, Terry Loustel was diagnosed with ALS in 2022. In his own words, Terry shares his journey—from receiving his diagnosis to navigating life with ALS—and why he has chosen to use his voice to advocate for the ALS community.

Shawn’s Story: Choosing Hope, Living Fully

At 57, Shawn lives in a small town in British Columbia’s northern Okanagan. He enjoys the beauty of the region and remains focused on living life to the fullest, despite an ALS diagnosis that arrived after a long and uncertain journey.
Shawn first noticed something was wrong in May 2022 when he developed a weak pinch grip in his left hand. What followed was more than a year of appointments, referrals, tests, and alternative explanations.

Examining the Impact of U.S. Drug Pricing Pressure on Canada

ALS Action Canada Advocacy Committee member Dr. Andrew Darke co-authored a Financial Post commentary examining how U.S. drug pricing pressure could affect Canada’s pharmaceutical landscape, investment and access to innovative treatments, including therapies for people living with ALS.